Treatment of respiratory syncytial virus with palivizumab: A systematic review

World Journal of Pediatrics

Volumn 6, Issue 4, 2010, Pages 296-300

  Hu, Jia ^a   Robinson, Joan L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

palivizumab; respiratory syncytial virus; respiratory tract infection

Indexed keywords

BETAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PALIVIZUMAB; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FEVER; DYSPNEA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; PNEUMONIA; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SIDE EFFECT; SUBGLOTTIC STENOSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TACHYCARDIA; TRACHEA MUCUS; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS CONCENTRATION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 78649683045     PISSN: 17088569     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12519-010-0230-z     Document Type: Article

References (22)

1. E. Whimbey J.A. Englund R.B. Couch 1997 Community respiratory virus infections in immunocompromised patients with cancer Am J Med 102 3A 10 18 1:STN:280:DC%2BD3czis1Wiuw%3D%3D 10.1016/S0002-9343(97)80004-6 10868137 (Pubitemid 27203564)
2. R.F. Robinson 2008 Impact of respiratory syncytial virus in the United States Am J Health Syst Pharm 65 23Suppl8 S3 S6 10.2146/ajhp080438 19020201
3. Committee on Infectious Diseases. 2009 From the American Academy of Pediatrics: policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections Pediatrics 124 1694 1701 10.1542/peds.2009-2345
4. The IMpact-RSV Study Group. 1998 Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 531 537 10.1542/peds.102.3.531 (Pubitemid 28409250)
5. T.F. Feltes A.K. Cabalka H.C. Meissner F.M. Piazza D.A. Carlin F.H. Top Jr, et al. 2003 Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J Pediatr 143 532 540 1:CAS:528:DC%2BD3sXot1Gktbw%3D 10.1067/S0022-3476(03)00454-2 14571236 (Pubitemid 37352516)
6. W.J. Rodriguez W.C. Gruber R.C. Welliver J.R. Groothuis E.A. Simoes H.C. Meissner, et al. 1997 Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group Pediatrics 99 454 461 1:STN:280: DyaK2s7ptlOiuw%3D%3D 10.1542/peds.99.3.454 9041304 (Pubitemid 27176021)
7. W.J. Rodriguez W.C. Gruber J.R. Groothuis E.A. Simoes A.J. Rosas M. Lepow, et al. 1997 Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children Pediatrics 100 937 942 1:STN:280:DyaK1c%2FkvFSntQ%3D%3D 10.1542/peds.100.6.937 9374560
8. R. Malley J. DeVincenzo O. Ramilo P.H. Dennehy H.C. Meissner W.C. Gruber, et al. 1998 Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein J Infect Dis 178 1555 1561 1:CAS:528:DyaK1MXnt1Sn 10.1086/314523 9815203 (Pubitemid 28558122)
9. M. Boeckh M.M. Berrey R.A. Bowden S.W. Crawford J. Balsley L. Corey 2001 Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants J Infect Dis 184 350 354 1:CAS:528:DC%2BD3MXlvFOhu7o%3D 10.1086/322043 11443562 (Pubitemid 32662183)
10. G.L. Banna S.M. Aversa A.M. Cattelan G. Crivellari S. Monfardini 2004 Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy Scand J Infect Dis 36 155 157 10.1080/00365540410019282 15061675 (Pubitemid 38313047)
11. X. Sáez-Llorens M.T. Moreno O. Ramilo P.J. Sánchez F.H. Top Jr E.M. Connor, et al. 2004 Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection Pediatr Infect Dis J 23 707 712 10.1097/01.inf.0000133165.85909.08 15295219 (Pubitemid 39063284)
12. S. Chávez-Bueno A. Mejías R.A. Merryman N. Ahmad H.S. Jafri O. Ramilo 2007 Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients Pediatr Infect Dis J 26 1089 1093 10.1097/INF.0b013e3181343b7e 18043443 (Pubitemid 350190938)
13. F.S. de Fontbrune M. Robin R. Porcher C. Scieux R.P. de Latour C. Ferry, et al. 2007 Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation Clin Infect Dis 45 1019 1024 10.1086/521912 17879919 (Pubitemid 47580353)
14. V. Liu G.S. Dhillon D. Weill 2010 A multi-drug regimen for respiratory syncytial virus and parainfl uenza virus infections in adult lung and heart-lung transplant recipients Transpl Infect Dis 12 38 44 1:CAS:528: DC%2BC3cXmtVWjsr8%3D 10.1111/j.1399-3062.2009.00453.x 19761558
15. J. Zybak B. Kassur-Siemienska J. Milczewska A. Wieteska-Klimczak 2007 The use of palivizumab in the treatment of a child with lower respiratory tract infection caused by respiratory syncytial virus-a case report Pediatria Polska 82 250 253
16. T. Stacy D.G. Connaghan H.K. Holland 2001 Empiric treatment of respiratory syncytial virus infection in adult stem cell transplant recipients with ribavirin and palivizumab Blood 96 343b
17. F.W. Cheng V. Lee M.M. Shing C.K. Li 2008 Prolonged shedding of respiratory syncytial virus in immunocompromised children: implication for hospital infection control J Hosp Infect 70 383 385 1:STN:280: DC%2BD1cjlslyiuw%3D%3D 10.1016/j.jhin.2008.08.014 18951664
18. A.J. Peck J.A. Englund J. Kuypers K.A. Guthrie L. Corey R. Morrow, et al. 2007 Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection Blood 110 1681 1688 1:CAS:528:DC%2BD2sXhtVSgsbnJ 10.1182/blood-2006-12-060343 17502457 (Pubitemid 47443987)
19. J.T. Schiffer K. Kirby B. Sandmaier R. Storb L. Corey M. Boeckh 2009 Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation Haematologica 94 1101 1108 10.3324/haematol.2008.003186 19644142
20. W.A. Prescott Jr F. Doloresco J. Brown J.A. Paladino 2010 Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review Pharmacoeconomics 28 279 293 10.2165/11531860-000000000-00000 20131925
21. R. Lagos J.P. DeVincenzo A. Muñoz M. Hultquist J. Suzich E.M. Connor, et al. 2009 Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children Pediatr Infect Dis J 28 835 837 10.1097/INF. 0b013e3181a165e4 19636278
22. Federal Drug Advisory, 2010. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AntiviralDrugsAdvisoryCommittee/UCM213827.pdfref (accessed August 17, 2010).